The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.

Authors:
El K; Douros JD; Willard FS; Novikoff A; Sargsyan A and 12 more

Journal:
Nat Metab

Publication Year: 2023

DOI:
10.1038/s42255-023-00811-0

PMCID:
PMC10290954

PMID:
37277609

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Nat Metab

Abbreviation: Nat Metab

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Proteolytic activation of fatty acid synthase signals pan-stress resolution.
Wei H; Weaver YM; Yang C and 6 more (2024) - Transparency Score: 4/6
Adipogenic and SWAT cells separate from a common progenitor in human brown and white adipose depots.
Palani NP; Horvath C; Timshel PN and 11 more (2023) - Transparency Score: 5/6
A phenome-wide comparative analysis of genetic discordance between obesity and type 2 diabetes.
Coral DE; Fernandez-Tajes J; Tsereteli N and 12 more (2023) - Transparency Score: 4/6
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.
Govaere O; Hasoon M; Alexander L and 10 more (2023) - Transparency Score: 4/6
Cell cycle-linked vacuolar pH dynamics regulate amino acid homeostasis and cell growth.
Okreglak V; Ling R; Ingaramo M and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"raw data source data table 1"

Code Sharing
Evidence found in paper:

"Competing interests The Campbell group receives funding for basic science from Novo Nordisk and Eli Lilly. The Müller group receives funding for basic science from Novo Nordisk. F.S.W., D.B.W. and K.W.S. are employees of Eli Lilly. J.D.D., B.Y. and B.F. are employees of Novo Nordisk. D.A.D. has served as a consultant or speaker within the past 12 months for Eli Lilly and Structure Therapeutics. J.E.C. has served as a consultant or speaker within the past 12 months for Structure Therapeutics. The remaining authors declare no competing interests or conflict of interest."

Evidence found in paper:

"Funding Open access funding provided by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025